Enliven Therapeutics (ELVN) Share-based Compensation (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Share-based Compensation data on file, last reported at $7.4 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 8.8% year-over-year to $7.4 million; the trailing twelve-month figure through Mar 2026 stood at $34.2 million (up 52.42% YoY), and the FY2025 full-year result was $34.0 million, up 68.63% from the prior year.
• Share-based Compensation slipped to $7.4 million in Q1 2026, from $12.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $12.3 million in Q4 2025 to a low of $654000.0 in Q1 2022.
• A 5-year average of $4.3 million and a median of $4.2 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation soared 498.43% in 2023 and tumbled 74.88% in 2025, its largest moves.
• Tracing ELVN's Share-based Compensation over 5 years: stood at $2.8 million in 2022, then climbed by 8.99% to $3.1 million in 2023, then jumped by 74.71% to $5.3 million in 2024, then soared by 130.59% to $12.3 million in 2025, then sank by 39.92% to $7.4 million in 2026.
• Business Quant data shows ELVN's Share-based Compensation at $7.4 million in Q1 2026, $12.3 million in Q4 2025, and $1.3 million in Q3 2025.